Multiple metabolic pathways fuel the truncated tricarboxylic acid cycle of the prostate to sustain constant citrate production and secretion

Lilianne Frégeau-Proulx1,2,3, Aurélie Lacouture1,2,3, Line Berthiaume1,3, Cindy Weidmann1,3, Mario Harvey1,3, Kevin Gonthier1,2,3, Jean-François Pelletier3,4, Bertrand Neveu3,4, Cynthia Jobin1,2,3, Dominic Bastien3,4, Alain Bergeron3,4,8, Yves Frade3,4,8, Louis Lacombe3,4,7, Isabelle Lavérdière3,4,6,7, Chantal Allal8, Frédéric Pouliot3,4,8, Étienne Audet-Walsh1,2,3.

ABSTRACT

Objective: The prostate is metabolically unique: it produces high levels of citrate for secretion via a truncated tricarboxylic acid (TCA) cycle to maintain male fertility. In prostate cancer (PCa), this phenotype is reprogrammed, making it an interesting therapeutic target. However, how the truncated prostate TCA cycle works is still not completely understood.

Methods: We optimized targeted metabolomics in mouse and human organoid models in ex vivo primary culture. We then used stable isotope tracer analyses to identify the pathways that fuel citrate synthesis.

Results: First, mouse and human organoids were shown to recapitulate the unique citrate-secretory program of the prostate, thus representing a novel model that reproduces this unusual metabolic profile. Using stable isotope tracer analysis, several key nutrients were shown to allow the completion of the prostate TCA cycle, revealing a much more complex metabolic profile than originally anticipated. Indeed, along with the known pathway of aspartate replenishing oxaloacetate, glutamine was shown to fuel citrate synthesis through both glutaminolysis and reductive carboxylation in a GLS1-dependent manner. In human organoids, aspartate entered the TCA cycle at the malate entry point, upstream of oxaloacetate. Our results demonstrate that the citrate-secretory phenotype of prostate organoids is supported by the known aspartate—oxaloacetate—citrate pathway, but also by at least three additional pathways: glutaminolysis, reductive carboxylation, and aspartate—malate conversion.

Conclusions: Our results add a significant new dimension to the prostate citrate-secretory phenotype, with at least four distinct pathways being involved in citrate synthesis. Better understanding this distinctive citrate metabolic program will have applications in both male fertility as well as in the development of novel targeted anti-metabolic therapies for PCa.

Keywords Prostate cancer; Organoids; TCA cycle; Androgen; Fertility

1. INTRODUCTION

Glucose, amino acids, and fatty acids can fuel mitochondrial activity through the tricarboxylic acid (TCA) cycle for ATP production. This cycle begins with the transfer of the two-carbon acetyl group from acetyl-CoA to the four-carbon acceptor oxaloacetate, which replenishes the two carbons lost during one cycle. This reaction forms the six-carbon citrate molecule, and the cycle continues. The prostate gland is metabolically unique: luminal epithelial cells have a truncated TCA cycle to produce, accumulate, and secrete high levels of citrate (Figure 1A) [1,2]. It has been proposed that these cells accumulate high zinc levels that inhibit the mitochondrial aconitase enzyme (ACO2), thus impairing citrate usage in the TCA cycle to allow its secretion [1—4]. This specialized citrate-secretory phenotype is an important function of the prostate gland for human reproduction because it maintains semen pH, buffers calcium ions, and participates in the coagulation/de-coagulation process. For example, in semen plasma, citrate has a high affinity for ions such as calcium, magnesium, and zinc. It acts as a buffer for calcium ions, and it is the major regulator of ionized calcium concentration in the semen [5]. Because calcium concentration is important to sperm count and motility, changes in citrate secretion has important implications for male fertility [6]. Seminal citrate levels are thus positively correlated with sperm count, morphology, motility, and volume [7].

1Endocrinology — Nephrology Research Axis, CHU de Québec — Université Laval Research Center, Québec, QC, Canada 2Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, QC, Canada 3Centre de Recherche sur le Cancer de l’Université Laval, Québec, QC, Canada 4Oncology Research Axis, CHU de Québec — Université Laval Research Center, Québec, QC, Canada 5Department of Surgery, Faculty of Medicine, Université Laval, Québec, QC, Canada 6Faculty of Pharmacy, Université Laval, Québec, QC, Canada 7Department of Pharmacy, CHU de Québec — Université Laval, Québec, QC, Canada 8Department of Pathology, CHU de Québec — Université Laval, Québec, QC, Canada

*Corresponding author. Centre de Recherche du CHU de Québec — Université Laval, 2705 Boulevard Laurier, Room R-4714, Québec, QC, G1V 4G2, Canada. E-mail: etienne.audet-walsh@crchudequebec.ulaval.ca (É. Audet-Walsh).

Received February 4, 2022 • Revision received May 16, 2022 • Accepted May 16, 2022 • Available online 20 May 2022

https://doi.org/10.1016/j.molmet.2022.101516
In addition to its role in male fertility, the alteration of the citrate-secretory phenotype is also tightly linked to prostate cancer (PCa). Indeed, during malignant transformation, citrate metabolism is reprogrammed, leading to a 10- to 100-fold decrease in citrate levels in tumors compared to peri-tumor tissues [3,8—10]. This loss of the citrate-secretory phenotype occurs in virtually all PCs cases, highlighting it as a hallmark of PCs [1—4,8—15]. Accordingly, decreases in prostate citrate levels can be detected using magnetic resonance spectroscopy, and several studies have identified this decrease in citrate as a biomarker for PCa diagnosis [16—18]. Moreover, lower intratumor citrate concentrations have been associated with shorter recurrence-free survival, suggesting that reprogramming of citrate is not only linked to carcinogenesis but also to PCa progression [19,20].

To better understand the truncated TCA cycle of the prostate, we leveraged mouse and human prostate organoid models combined with mass spectrometry (MS)-based metabolomics. First, we show that these organoids recapitulate the unique citrate-secretory program of this gland, being—to our knowledge—a unique model that reproduces this unusual metabolic profile. Using stable isotope tracer analysis, we identified several key nutrients that allow completion of the truncated TCA cycle in these prostate organoids and revealed a much more complex metabolic profile than originally anticipated. These results, obtained with both mouse and human prostate organoids, support the model depicting that the unique TCA cycle of the prostate is much more flexible than anticipated, with several nutrients fueling it at different entry points to support both citrate production and energy synthesis.

2. MATERIAL AND METHODS

2.1. Purification of mouse prostate epithelial cells for primary culture

All mouse work was performed according to Université Laval’s Animal Research and Ethics Committee’s guidelines and regulations. Mice (C57BL/6) were bred, housed in a 12 h light:12 h dark cycle at 22 °C, and handled at the animal care facility of the Centre de recherche du CHU de Québec — Université Laval. Purification of prostate epithelial cells was adapted from the protocol of Lacouture et al. for purification of mammary epithelial cells [34]. All volumes shown below are for purification of epithelial cells using four mice at 12 weeks of age. After sacrifice, prostates were surgically collected and maintained in 1× complete HBSS solution (hBSS + 2% FBS + 10 mM HEPES + 100 U/ mL penicillin and 100 μg/mL streptomycin [Wisent]). Prostates were then minced with scissors under a biological hood and transferred to a tube containing 4 mL of a 1× complete EpiCult-B mouse medium with 5% FBS (EpiCult basal medium [STEMCELL technologies], 10 ng/mL Recombinant human EGF [STEMCELL technologies], 10 ng/mL recombinant human bFGF [STEMCELL technologies], 4 μg/mL heparin [Sigma—Aldrich], 100 U/mL penicillin, 100 μg/mL streptomycin, 10% EpiCult proliferation supplement [STEMCELL technologies]) with 1 mL of 1× Gentle Collagenase/Hyaluronidase solution (STEMCELL technologies) for a 2 h incubation at 37 °C. The solution was then gently mixed by pipetting followed by a centrifugation at 350 g for 5 min. The supernatant was discarded and the pellet resuspended with 1 mL of warm 0.25% trypsin—EDTA (Wisent). After 1 min of gentle pipetting, 4 mL of 0.25% trypsin—EDTA was added followed by 1 min of gentle pipetting. After 1 h of incubation on ice, 10 mL of 1× complete HBSS solution was added; the tube was inverted two or three times before centrifugation at 350 g for 5 min. After removal of the supernatant, 2 mL of warm dispase (5 U/mL — STEMCELL technologies) and 200 μL of 1 mg/mL of DNase I (Roche) were added. After pipetting for 1—3 min to dissociate clumps, 10 mL of cold 1× complete HBSS solution was added and the tube inverted 2—3 times before filtration through a 40 μm Cell Strainer (Falcon). The cells were centrifugated for 5 min at 350 g and were resuspended in 1 mL of 1× complete EpiCult-B mouse medium with 5% FBS for counting. Cells were purified using the EasySep Mouse PE Positive Selection kit II (#17666, STEMCELL technologies) according to the manufacturer’s protocol with 10 μL of CD49-PE antibody (#555736, BD Biosciences) for 20 × 10^5 cells. The obtained cells were centrifuged and counted.

2.2. Primary culture of mouse epithelial cells

For two-dimensional culture, the purified cells were centrifuged 5 min at 350 g and resuspended in Keratinocyte serum-free medium (KSFIM), with

Original Article
1 × penicillin and streptomycin [GIBCO], 10 μM of the anti-ROCK inhibitor Y-27632 (Tocris), cholera toxin (4 ng/mL) [Sigma—Aldrich], and the TGF-β pathway inhibitor A 83-01 (500 nM) [MilliporeSigma]. The suspension was plated in 0.003% poly-L-lysine-coated (Sigma—Aldrich) culture dishes and kept in a 37 °C incubator with 5% CO₂. The medium was changed every three days. When reaching confluence, cells were detached with TrypLE (GIBCO) supplemented with 10 μM Y-27632 for 5 min at 37 °C and scraped gently before plating in poly-L-lysine coated culture dishes. For three-dimensional culture, cells were resuspended in complete EpiCult-B mouse medium with 5% FBS and used to produce 40 μL droplets containing 75% of growth factor reduced Matrigel (Corning). Each droplet, containing 30,000 to 60,000 cells depending on the experiment, was seeded using cold tips in a warm culture dish. After plates were incubated 15 min upside down at 37 °C, warm complete EpiCult-B mouse medium with 5% FBS was added to each well to cover Matrigel droplets. After 24 h, the medium was changed for serum-free EpiCult-B mouse medium (EpiCult basal medium, 10% EpiCult proliferation supplement, 10 ng/mL recombinant human EGF, 10 ng/mL recombinant human bFGF, 4 μg/mL heparin, 100 U/mL penicillin, and 100 μg/mL streptomycin) and replaced every three days.

2.3. Cell labeling and flow cytometry analysis

Before and after mouse epithelial cell purification, 250,000 cells were resuspended in 100 μL of FACS buffer (5% FBS + 0.05% sodium azide in PBS) and stained with CD24-APC (clone M1/69, BioLegend) and CD49F-PE (clone GoH3, Biosciences), or the isotype control antibodies, at the manufacturer’s recommended dilution. Antibodies were incubated at room temperature for 30 min and then cells were washed twice in FACS buffer. Data were acquired using a BD FACSCelesta™ Flow Cytometer and BD FACSDiva™ software version 8.0.1.1 (Becton, Dickinson and Company). Data analysis was performed using FlowJo™ version 10.7.1 (Becton, Dickinson and Company). Ten thousand events were acquired for each sample. Isotype controls were used to set the gates.

2.4. Histology, immunofluorescence, and microscopy analyses

Matrigel droplets were fixed in 3% agarose. Briefly, 1 mL of 1 × PBS was added in each well and droplets were scraped gently and moved to a 1.5 mL micro-centrifuge tube. Matrigel droplets were centrifuged at 2500 g for 2 min at 4 °C. The supernatant was discarded, and the pellet was washed with 1.5 mL of 1 × PBS, and centrifuged at 2500 g for 2 min at 4 °C. Matrigel droplets were fixed with 4% paraformaldehyde for 1 h at room temperature and then centrifuged at 2500 g for 3 min at 4 °C. The supernatant was discarded and a few drops of 3% agarose were added. The fixed agarose drops were transferred to histological cassettes and were again fixed overnight in 10% formalin before being embedded in paraffin (Laboratoire de pathologie de l’Hôtel-Dieu de Québec). The paraffin-embedded organoids were cut into 5 μm sections with a microtome (HistoCore MULTICUT 14051856372, Leica) for H&E staining. Images were taken with an EVOS™ M5000 Imaging System (ThermoFisher Scientific).

For immunofluorescence, each slide was deparaffinized and rehydrated. An antigen retrieval step was performed with the Diva Decloaker (DV2005 L2J) by Biocare and the slides were incubated overnight at 60 °C. A blocking step was also performed with TBS 1× — 1% BSA — 5% FBS for 2 h at room temperature. For immuno-fluorescence, each slide was deparaffinized and rehydrated. An antigen retrieval step was performed with the Diva Decloaker (DV2005 L2J) by Biocare and the slides were incubated overnight at 60 °C. A blocking step was also performed with TBS 1× — 1% BSA — 5% FBS for 2 h at room temperature. For immuno-fluorescence, each slide was deparaffinized and rehydrated. An antigen retrieval step was performed with the Diva Decloaker (DV2005 L2J) by Biocare and the slides were incubated overnight at 60 °C. A blocking step was also performed with TBS 1× — 1% BSA — 5% FBS for 2 h at room temperature. For immuno-fluorescence, each slide was deparaffinized and rehydrated. An antigen retrieval step was performed with the Diva Decloaker (DV2005 L2J) by Biocare and the slides were incubated overnight at 60 °C. A blocking step was also performed with TBS 1× — 1% BSA — 5% FBS for 2 h at room temperature. For immuno-fluorescence, each slide was deparaffinized and rehydrated. An antigen retrieval step was performed with the Diva Decloaker (DV2005 L2J) by Biocare and the slides were incubated overnight at 60 °C. A blocking step was also performed with TBS 1× — 1% BSA — 5% FBS for 2 h at room temperature. For immuno-fluorescence, each slide was deparaffinized and rehydrated. An antigen retrieval step was performed with the Diva Decloaker (DV2005 L2J) by Biocare and the slides were incubated overnight at 60 °C. A blocking step was also performed with TBS 1× — 1% BSA — 5% FBS for 2 h at room temperature.

2.5. Cell viability assay

AlamarBlue Cell Viability Reagent (#1100, Invitrogen) was used to determine cell viability with and without trypsin dissociation. Organoids without dissociation were scraped in complete Epicult media, and 10% AlamarBlue Cell Viability Reagent was added to each well before incubation at 37 °C for 30 min. For dissociation, trypsin was added to the organoids for 3 min before harvest in media. Organoids were then incubated at 37 °C for 30 min with 10% AlamarBlue Cell Viability Reagent. Wells with media, Matrigel, and AlamarBlue but without organoids were used as negative controls. Finally, fluorescence was measured at 570 nm of excitation and 585 nm of emission using a spectrophotometer. Student’s t-tests were used to evaluate statistical significance.

2.6. Human primary prostate cell culture conditions

Human prostate tissues were obtained, with consent, from men undergoing radical prostatectomy as treatment for their cancer. This research was approved by the research ethics committee of the CHU de Québec — Université Laval (Project 2021-5661). Briefly, after resection, 14G-punch biopsies (1–4) were taken in the prostate under the supervision of a pathologist and put into 1 × complete HBSS. Biopsies were transferred to the lab and then processed as described for enzymatic digestion of mouse prostates. Cells were suspended in KSFM with 10 μM of the anti-ROCK inhibitor Y-27632, cholera toxin (4 ng/mL), and the TGF-β pathway inhibitor A 83-01 (500 nM). Thereafter, they were seeded at cell densities ranging between 250,000 and 500,000 in poly-L-lysine-treated 10 cm culture dishes; medium was changed twice a week. For passages, cells were detached with TrypLE supplemented with 10 μM Y-27632. For three-dimensional culture, cells were passaged using TrypLE and resuspended after centrifugation in complete human organoid medium (complete KSFM, 1 × penicillin and streptomycin, 4% B27 supplements [STEMCELL technologies], 10 μM Calcitriol [Cayman Chemical], 10 nM testosterone, and 10 μM Y-27632) and used to produce 40 μL droplets containing 75% of growth-factor—reduced Matrigel. Each droplet, containing 15,000 to 30,000 cells depending on the experiment, was seeded using cold pipette tips in a warm culture dish. After plates were incubated for 15 min upside down at 37 °C, warm complete human organoid media was added to each well to cover the Matrigel droplets. Media was renewed twice a week for the duration of the experiments.

2.7. Gas chromatography — mass spectrometry

Mouse and human prostate organoids were cultured for two weeks with and without incubation with 13C-labeled nutrients (during the last 72 h) and then harvested for GC—MS analyses. When harvested without dissociation, 1 mL of media was first harvested, centrifuged 5 min at 10,000 g, and the supernatant was transferred to a new 1.5 mL tube. In parallel, organoids were rinsed with ice-cold saline on ice before being harvested on dry ice with dry-ice-cold 80% MeOH. Extracellular media and organoids were both flash frozen and stored at −80 °C until GC—MS analysis. When harvested with dissociation, media was harvested in a 15 mL tube and trypsin was added to the organoids. Organoid plates were returned to 37 °C for 3 min. Dissociation was finalized by returning media culture to the respective organoids well, pipetting it up and down 10 times, and transferring it to a new 15 mL tube. Organoids with media were centrifuged 5 min at 11001, Invitrogen) were incubated for 1 h at room temperature. Finally, FluoromounT-G with DAPI (00-4959-52, ThermoFisher Scientific) was added. Images were taken with an EVOS™ M5000 Imaging System (ThermoFisher Scientific).
800 g. The supernatant, containing organoid secretion, was then transferred to a new tube, flash frozen, and stored at −80 °C. Organoids were washed once with ice-cold saline, centrifuged 5 min at 800 g at 4 °C, and then mixed with dry-ice-cold 80% MeOH. All samples were kept at −80 °C until analyses. On the day of analyses, organoids were lysed by sonication and centrifuged at 20,000 g for 10 min [34]. For culture media, 200 μL of media was mixed with 400 μL of dry-ice-cold 80% MeOH before centrifugation at 20,000 g for 10 min. After centrifugation of either media or organoids, supernatant was transferred into a new tube containing the internal standard Myristic acid-d27 (CDN Isotopes, Canada), to which 700 μL acetonitrile (ACN) was added. Samples were vortexed, centrifuged, and the supernatant was recovered to be dried using nitrogen gas. A two-step derivatization protocol was then performed: 1) methoxyamination with the method described by Fiehn [35] and 2) silylation with MTBSTFA/TBDMCS using the modified method from Patel et al. [36]. Finally, samples were analyzed with GC–MS using an Agilent 8890 GC equipped with a DB5-MS+ DG capillary column connected to an Agilent 5977B MS operating under electron ionization (EI) ionization at 70 eV (Agilent Technologies, Santa Clara, CA, USA). For all samples, 1 μL was injected in split mode at 250 °C. Helium was the carrier gas (flow rate of 1 mL/min). The temperature of the GC oven was held at 50 °C for 2 min, then raised to 150 °C at a rate of 20 °C/min for 5 min, and from 150 °C to 300 °C at a rate of 10 °C/min; column temperature was then kept constant at 300 °C for another 10 min. The MS source and quadrupole were held at 230 °C and 150 °C, respectively, and the detector was operated in scanning mode for mass range 50–600 Da at a signal rate of 5.1 scans/sec. Analyses were made using the Agilent MassHunter Workstation Software. After deconvolution, metabolites were identified using the NIST/EPA/NIH Mass Spectral Library (NIST 2017, Gaithersburg, MD, USA). To perform absolute quantification, TCA cycle intermediate standards were used in parallel; other metabolites were shown in relative quantification after normalization with the internal standard (myristic acid-d27). For 13C-glucose (#CLM-1396-PK, Cambridge Isotope Laboratories, Inc.), 13C-aspartate (#49899, Sigma—Aldrich), and 13C-glutamine (#CLM-1822-H-0.1MG, Cambridge Isotope Laboratories, Inc.), we used concentrations of 10 mM, 1 mM, and 2 mM in culture media, respectively. They were injected directly into either KSFM or Epicult-B mouse media, both containing unlabeled glucose and glutamine but low levels of aspartate (not detectable by GC–MS). After incubation with tracers, organoids were harvested and analyzed by GC–MS as described above. For treatment with inhibitors, 13C-nutrients were added simultaneously to 6 μM of bis-2-(5-phenylacetamido-1,3,4-thiadiazol-2-yl)ethyl sulfide (BPTES; Selleckchem). Note that in parallel with being harvested for GC–MS analyses, additional organoids were dissociated for cell counting that was used to normalize metabolomic data for cellular content. For metabolomic analyses of mouse tissues, adult mice were sacrificed and organs harvested before being flash frozen and stored at −80 °C. Tissues were ground with a mortar using liquid nitrogen on dry ice. Tissue powder was weighed and resuspended in dry-ice-cold 80% MeOH before being processed as described above for organoids. Student’s t-tests were used to evaluate statistical significance.

3. RESULTS AND DISCUSSION

3.1. Describing the metabolic profile of the mouse prostate
We first studied the metabolic profile of the mouse prostate, focusing on the TCA cycle, and compared it to several other tissues, including liver, heart, and brown adipose tissue. Citrate was highly enriched in the prostate, with an average of 2.2 μmol/g (Figure 1B). These levels were 28- to 52-fold higher than those in all the other tissues studied, which had levels near ~0.05 μmol/g (50 ng/mol/g). We next measured the levels of the TCA cycle intermediate cis-aconitate. While its levels were lower compared to citrate in the prostate, with an average of 0.23 μmol/g (Figure 1C), it was four to 10 times higher than any other tissue. These results suggest that citrate strongly accumulates in the prostate, but that a significant proportion can nevertheless continue in the TCA cycle. Succinate, fumarate, and malate levels were similar across all the tissues tested, including the prostate (Figure 1D–F). Other TCA cycle intermediates were either not detected or could not be interrogated using our GC–MS approach in mouse tissues. If the cycle was completely truncated in the prostate, as expected from the actual model, one would assume that downstream intermediates would be much lower in terms of absolute concentrations. These results suggest that nutrients downstream of citrate but upstream of oxaloacetate allow the completion of the TCA cycle in the prostate.

Another intriguing question is whether prostate epithelial cells exhibit mitochondrial respiration and, if not, how do they produce ATP. Based on rat prostate extracts, it is thought that these cells mainly depend on aerobic glycolysis for energy synthesis [23,24]. However, in vivo imaging data shows low glycolytic activity in the normal prostate [27–29]. Furthermore, recent work has demonstrated that prostate tissues have detectable mitochondrial respiration despite exhibiting a truncated TCA cycle [26]. We hypothesized that the dependency on aerobic glycolysis would not be as strong as currently assumed, and thus we also measured lactate (Figure 1G). The prostate, along with the testis, showed the lowest lactate levels (Figure 1G). Such a result does not indicate that this organ relies principally on aerobic glycolysis for energy synthesis. Other metabolites were measured, including several amino acids, but none showed specific enrichment in the prostate (Supplemental Figure S1). Altogether, these results suggest that despite massive citrate production, the prostate nevertheless exhibits significant levels of the different TCA cycle intermediates, suggesting an alternative cycle that is not solely composed of oxaloacetate and citrate.

3.2. Mouse prostate organoids exhibit the citrate-secretory phenotype
To better understand the prostate-specific citrate metabolic program, we next optimized a protocol for FACS-free purification of mouse prostate epithelial cells and their primary culture ex vivo (see section two for details). In brief, the prostate is harvested and processed through sequential enzymatic digestions to obtain a single-cell suspension. Epithelial cells are then purified using magnetic beads. This protocol allows high enrichment of basal and luminal epithelial cells, as shown by flow cytometry (Figure 2A and Supplemental Figure S2A). After purification, cells can be plated for primary culture in two dimensions (Supplemental Figure S2B) or be used for organoid culture in three dimensions (Figure 2B). Organoids began to be visible after three days in culture and continuously grew for 12–14 days, at which time they reached their maximum size (Figure 2B). The prostate gland is known to require androgens to activate the androgen receptor (AR), which promotes growth and survival, and testosterone had a significant impact on organoid growth (Figure 2B and C). This positive regulation by AR was associated with an increased size of the organoids, but with no change in the total number of organoids (Supplemental Figure S2C). Histological staining with hematoxylin and eosin (H&E) shows the glandular structure of the prostate organoids, i.e., the organization of cells surrounding an internal lumen, which are
Figure 1: The prostate exhibits a unique truncated TCA cycle that supports massive citrate production. A) Current working model of the prostate’s truncated TCA cycle. Citrate is massively produced by prostate epithelial cells and secreted into the seminal fluid; this is a well-known phenotype associated with fertility. Several nutrients could fuel the prostate TCA cycle, including glucose, fatty acids, glutamate, and aspartate. It is currently assumed that glucose and aspartate are the major carbon sources required for citrate production and secretion. B–G) Targeted metabolomics of TCA cycle intermediates and lactate in various mouse tissues. Results are shown as the average ± SEM of two independent experiments comprising organs from seven mice. Results are shown for the prostate (yellow) and other organs (blue) in μmol/g of tissues. SAT: Brown adipose tissue. Additional metabolites quantified are available in Supplemental Figure S1.

Further increased with the androgen testosterone (Figure 2C). Given the positive impact of androgens on organoid growth, all subsequent experiments were performed in the presence of testosterone.

The prostate gland secretes within internal lumens, and the presence of such a structure in prostate organoids led us to hypothesize that these organoids could recapitulate the in vivo secretory functions of the prostate and thus secrete citrate in these lumens. To test this hypothesis, we performed gas chromatography—mass spectrometry (GC–MS) targeted metabolomics in organoids to detect citrate secretion within their lumen. With an intact organoid, the internal lumen is not connected to the extracellular media. However, we hypothesized that dissociation of the 3D architecture with trypsin would allow internal secretions to be released to capture metabolites secreted from luminal cells (Figure 2D). In the absence of dissociation, several metabolites were quantified in the extracellular media, including low levels of citrate as well as other TCA cycle intermediates, i.e., αKG and malate (Figure 2E and Supplemental Figure S2D). After organoid dissociation, the levels of several metabolites did not change while others had significantly increased (Figure 2E and Supplemental Figure S2D). Of all the metabolites tested, citrate had the biggest change (3.25 fold) compared to all other differences, which were all below a 1.73-fold change, except for malate (2.42 fold). It must also be kept in mind that the volume of luminal secretion is believed to be low compared to the volume of extracellular media. Thus, to allow changes in the extracellular concentrations, a metabolite must be present at high concentrations within luminal secretion. These results show that prostate organoids secrete citrate as well as other metabolites into their internal lumen. To avoid the possibility that dissociation—even if brief—would induce cell death and the release of metabolites, we studied cellular viability following our dissociation protocol. No differences were observed with or without the dissociation procedures (Supplemental Figure S2E). Overall, these results show a unique prostate model that exhibits the distinctive citrate-secretory phenotype of the prostate ex vivo.

3.3. Glucose, glutamine, and aspartate can fuel citrate production in mouse prostate organoids

Next, we wanted to determine the different nutrients providing carbon to the prostate-specific TCA cycle. To do so, we used stable isotope tracer analysis using 13C-labeled nutrients. We focused on glucose and aspartate, which are currently thought to be the major carbon sources required for citrate secretion [11,33] (Figure 3A). We also studied glutamine, the most abundant amino acid in circulation, which could sustain mitochondrial respiration by replenishing αKG (Figure 3A). Organoids were thus incubated with 13C6-glucose, 13C5-glutamine, or 13C5-aspartate for 72 h, a time-point that maximizes labeling compared to shorter periods (data not shown). Glucose (10 mM) and glutamine (2 mM) concentrations were close to the physiological concentrations in circulation, while aspartate (1 mM) was close to the intra-prostatic tissue concentration (Figure S1). After incubation with the different tracers, organoids were dissociated to harvest both organoids and their luminal secretion. Note that upon GC–MS analysis, aspartate was shown to be labeled with either one, two, three, or four 13C, but usually with only one or two 13C (Supplemental Figure S3A).

In organoids, the use of 13C6-glucose and 13C5-glutamine led to a 24% and 20% labeling in citrate, respectively, while labeling with aspartate was minor (<1%) (Figure 3B). As expected, citrate was mainly labeled in m + 2 and m + 4 from 13C6-glucose and 13C5-glutamine, respectively, thus fueling a “canonical” TCA cycle. 13C5-glutamine also
showed enrichment in citrate m+5, possibly indicating that reductive carboxylation can occur to support citrate production (Figure 3B). Cis-aconitate, zKG, and fumarate were below limits of quantification in organoids, but succinate and malate were quantifiable. As we expected given the truncation of the cycle, a much lower labeling in succinate and malate by 13C6-glucose was detected, mostly labeling them in m+2 (Figure 3C and 3D). 13C5-glutamine mostly led to succinate and malate labeling in m+4, consistent with its entry point from zKG (Figure 3A). Altogether, these results demonstrate that glutamine along with glucose is a major nutrient fueling TCA cycle activity in prostate organoids, bypassing the ACO2 inhibited step of the cycle and allowing a functional cycle to operate. This is important, as glutamine-supported TCA cycle activity allows mitochondrial respiration and ATP synthesis [37,38]. This probably explains why prostate mitochondria have detectable respiration [25,26] and also why prostate epithelial cells do not solely rely on aerobic glycolysis.

Labeling from 13C6-glucose downstream citrate was detected, indicating that a small fraction of the carbons used from glucose to produce citrate can also be used downstream in the TCA cycle, consistent with in vivo results showing cis-aconitate in the prostate (Figure 1). In parallel, metabolomics was also performed in luminal secretion, notably in secreted citrate. 13C6-glucose and 13C5-glutamine showed labeling patterns similar to those seen in organoids, with ~20–25% labeling in secreted citrate isomers (Figure 3E). In addition, 13C1-glutamate led to significant labeling of secreted citrate, with ~12% labeled citrate (Figure 3E). These results confirm that aspartate can contribute to the production of citrate for secretion, though to a lesser extent compared to glucose and malate. The fraction of 13C labeling in succinate and malate remained the same in secreted metabolites (Supplemental Figs. S3B and S3C) compared to intra-organoid levels (Figure 3C and 3D).

To better understand the relationship between glutamine and citrate synthesis, we next performed metabolomics using mouse prostate organoids treated or not with BPTES. This drug inhibits the glutaminase 1 enzyme (GLS1), which allows the conversion of glutamine into glutamate that can then be converted to αKG to enter the TCA cycle. After 11 days in culture, organoids were treated for 72 h with 6 μM, which did not induce major changes in organoid growth or viability (Supplemental Figure S3D). Interestingly, treatment with BPTES significantly decreased carbon flux from glutamine into glutamate, the product of GLS1, and blocked flux into the TCA cycle, confirming that GLS1 is an essential entry point of glutamine metabolism in prostate organoids for citrate synthesis (Figure 3F).

Altogether, these results using organoids suggest that the prostate citrate-secretory profile is more complex than originally anticipated. First, mouse prostate organoids exhibit a TCA cycle than is not only comprised of oxaloacetate-citrate. Second, glutamine is a major nutrient fueling the truncated TCA cycle at the αKG entry point—a well-known pathway that allows mitochondrial respiration. Third, glutamine could also fuel citrate production through reductive carboxylation. Fourth, as initially reported, both glucose and aspartate indeed support citrate production and secretion. Fifth, contrary to what was assumed, despite supporting citrate secretion, aspartate is not essential for citrate synthesis. Indeed, media used for organoid culture contains only low aspartate levels (in the low μM range). Results from Figures 2 and 3 thus indicate that aspartate is not, per se, an essential
amino acid required for massive citrate production and secretion. However, when supplemented, aspartate did support citrate production for secretion. Consequently, the distinctive citrate-secretory phenotype of mouse prostate organoids is not only comprised of one metabolic pathway, but it can be supported by at least three alternative pathways, including glutaminolysis, reductive carboxylation, and aspartate–oxaloacetate conversion. How these results obtained in mouse models apply to the human prostate is currently unknown.

3.4. Stable isotope tracer analyses in human prostate organoids

Finally, we wanted to determine whether the results obtained with mouse prostate organoids also hold for human prostate organoids. Indeed, the citrate-secretory phenotype of mouse prostate organoids is not only comprised of one metabolic pathway, but it can be supported by at least three alternative pathways, including glutaminolysis, reductive carboxylation, and aspartate–oxaloacetate conversion. How these results obtained in mouse models apply to the human prostate is currently unknown.

3.4. Stable isotope tracer analyses in human prostate organoids

Finally, we wanted to determine whether the results obtained with mouse prostate organoids also hold for human prostate organoids. Indeed, the citrate-secretory phenotype of mouse prostate organoids is not only comprised of one metabolic pathway, but it can be supported by at least three alternative pathways, including glutaminolysis, reductive carboxylation, and aspartate–oxaloacetate conversion. How these results obtained in mouse models apply to the human prostate is currently unknown.

Figure 3: Contribution of glucose, glutamine, and aspartate to the prostate organoid TCA cycle. A) Schematic representation of respective carbon contributions when organoids are supplemented with 13C6-glucose, 13C5-glutamine, or 13C1-4-aspartate, assuming aspartate carbons enter the cycle via oxaloacetate. For graphical purposes, aspartate is shown as 13C2-aspartate, but labeling in B–E can be observed from 13C1-, 13C2-, 13C3-, or 13C4-aspartate. Stable isotope tracer analyses in organoids using in parallel these three tracers are then shown for citrate (B), succinate (C), and malate (D), as well as for extracellular levels of citrate (E). After 11 days in culture, organoids were incubated for 72 h with 13C6-glucose, 13C5-glutamine, or 13C1-4-aspartate before being dissociated and harvested for GC–MS analyses. “All” indicates the sum of all isotopomers for a given metabolite. Statistics were only calculated using the sum of all isotopomers of a given metabolite. Results are shown as the average ± SEM of one representative experiment performed in triplicate out of three independent experiments. For these tracer experiments, note that organoids were cultured in parallel with the different 13C-labeled nutrients. Secreted succinate and malate labeling is shown in Supplemental Figure S3. F) Stable isotope tracer analysis in organoids following 72 h exposure to 13C5-glutamine, with and without the GLS1 inhibitor BPTES. After 72 h, organoids and luminal secretion (media) were harvested for metabolomics. For glutamine and glutamate, m + 5 labeling is shown; for TCA cycle intermediates, as labeling patterns were more complex (as shown in B–E), the sum of total labeling is shown (as shown in B–E). Results are shown as the average ± SEM of one representative experiment performed in triplicates out of two independent experiments. ***p < 0.001; **p < 0.01; *p < 0.05.
dissociation, reinforcing the idea that citrate is released from internal lumens after dissociation (Figure 4D). Several other metabolites were detected in the extracellular media, some being increased and some being unchanged by dissociation (Figure 4E and Supplemental Figure S4D). Finally, stable isotope tracer analyses were performed with a 72 h treatment with $^{13}$C$_6$-glucose, $^{13}$C$_1$-$^4$-aspartate, or $^{13}$C$_5$-glutamine before dissociation and harvest of luminal secretion and organoids. In human organoids, citrate labeling was predominately from $^{13}$C$_6$-glucose; there was up to 18% labeling (Figure 4F). $^{13}$C$_1$-$^4$-aspartate and $^{13}$C$_5$-glutamine both led to 5–8% labeling in intracellular organoid citrate levels (Figure 4F). Intracellular levels of succinate and malate were also detectable (Figure 4G and 4H). For succinate, carbon labeling was similar to what was observed in mouse organoids (Figure 3C), indicating a major contribution of glucose and glutamine to their carbon pools and as anticipated from the different entry points of these nutrients in the TCA cycle (Figure 3A).

For malate, labeling patterns were different in human organoids compared to mouse organoids. First, only modest labeling with $^{13}$C$_5$-glutamine was observed. Second, $^{13}$C$_1$-$^4$-aspartate labeling patterns indicated that aspartate is a major contributor to malate synthesis in human organoids, with up to 14% labeling. We cannot rule out that these differences between mouse and human organoids are not caused by differences in culture conditions. Most notably, due to the limited availability of fresh tissue, human prostate epithelial cells are first expanded in 2D culture before being passaged for organoid formation. In that context, it is possible that some changes occur compared to the native prostate gland in vivo. Nevertheless, these results suggest that, in human prostate organoids, aspartate fuels the TCA cycle upstream of oxaloacetate to synthesize malate and supports citrate secretion in a system that looks like the malate–aspartate shuttle. This shuttle, composed of four enzymes and two transporters, allows the shuttling of electrons between the cytosol and the

![Figure 4: Metabolomics analyses in human prostate organoids. A) Brightfield visualization of normal human prostate organoids over 12 days in three-dimensional culture. Organoid cultures derived from two different human patients are shown. Scale bars = 200 μm. B) H&E visualization of patient-derived prostate organoids showing the presence of internal lumen, demonstrated by black arrows. Scale bars = 125 μm and 50 μm, respectively, for 10× and 40× view. C) Brief treatment with trypsin (3 min) disrupts the three-dimensional architecture of human prostate organoids to allow connection of the internal lumen with the extracellular media. Scale bars = 200 μm. Representative images from patient #1 are shown and images for patient-derived organoids from patient #2 are available in Supplemental Figure S4C. D) Intra-organoid and extracellular citrate level quantification by GC–MS, with and without dissociation as shown in C. With dissociation, media contains luminal secretion. E) GC–MS metabolite quantification in extracellular culture media of human prostate organoids, with and without dissociation, as shown in C. For D and E, results are shown as the average ± SEM of one representative experiment performed in triplicate out of three independent experiments. Pyroglu: pyroglutamate. Stable isotope tracer analysis in organoids using $^{13}$C$_6$-glucose, $^{13}$C$_5$-glutamine, or $^{13}$C$_1$-$^4$-aspartate tracers is then shown for intra-organoid citrate (F), succinate (G), and malate (H) levels, as well as for secreted citrate levels (I). For results shown in F–I organoids were dissociated before GC–MS metabolomics quantifications. Results are shown as the average ± SEM of one representative experiment performed in triplicates out of two independent experiments for patient #1. For these tracer experiments, note that organoids were cultured in parallel with the different $^{13}$C-labeled nutrients. Similar results were obtained with organoids from patient #2 and are shown in Supplemental Figure S4. N.d.: not detectable or below the limit of quantification. “All” indicates the sum of all shown isotopomers for a given metabolite. Statistics were only calculated using the sum of all isotopomers of a given metabolite. ***p < 0.001; **p < 0.01; *p < 0.05.
mitochondria in the form of reduced malate, to replenish mitochondrial pools of NADH. Cytosolic GOT1 uses aspartate to synthesize oxaloacetate that can be reduced to malate by MDH1. This cytosolic malate is then shuttled to the mitochondria to be oxidized back to oxaloacetate by MDH2, and it can then be used for citrate synthesis in the prostate. Furthermore, $^{13}$C-labeling in secreted citrate was very similar to intracellular human organoid labeling, with major labeling with $^{13}$C-glucose and similar contributions from both $^{13}$C-glutamine and $^{13}$C-glucose and glutamine, aspartate, and glucose were validated using a second patient-derived organoid model (Supplemental Figure 4F). Results show high homogeneity between patient-derived organoids, again indicative of major contribution of all three nutrients to the TCA cycle and an entry point for aspartate through malate in these prostate models.

4. CONCLUSION

In summary, using stable isotope tracer analyses in mouse and human prostate models, we demonstrated that they retain a prostate citrate-secretory profile, and that this profile is far more complex than originally anticipated for the prostate gland. First, our results support the model where aspartate can replenish intermediates from the TCA cycle, notably citrate, but suggest that the prostate TCA cycle is not solely dependent on aspartate to replenish the four carbons of oxaloacetate to continuously produce citrate. Interestingly, aspartate also fueled the TCA cycle at the entry point. Next, glutamine was shown to be a major nutrient used to synthesize citrate from both oxidative and reductive pathways. Importantly, glutamine usage to replenish carbons at the oxaloacetate entry point allows mitochondrial respiration, probably explaining at least in part how prostate epithelial cells can regenerate their ATP. Overall, our results add a significant new dimension to the prostate citrate-secretory phenotype that can be supported by the known aspartate—oxaloacetate—citrate pathway, but also by three additional pathways: glutaminolysis, reductive carboxylation, and aspartate—malate conversion. We thus present updated working models of mouse and human prostate citrate metabolism (Figure 5). Future work will be important to validate these findings in vivo.

Future studies will allow a better understanding of prostate metabolism in both human physiology and disease. Indeed, better comprehension of the prostate’s distinctive citrate metabolic program will have potential applications in both male fertility and clinical management of PCs. Imaging analysis of intra-prostatic citrate levels showed that decreased levels of this metabolite are associated with PCA progression [19,20]. However, citrate is often studied individually or with other metabolites such as choline in imaging studies, but restored citrate flux through the TCA cycle is predicted to increase downstream TCA intermediates, such as malate and fumarate. It would be interesting to see whether the ratio of citrate with TCA metabolites specifically can better predict PCA prognosis. Moreover, better understanding how the unique citrate metabolic profile of the prostate is reprogrammed in PCs might also allow the development of novel targeted anti-metabolic therapies for PCs.

AUTHOR CONTRIBUTIONS

L.F.P. performed experiments, analyzed results, and helped write the manuscript. A.L., L.B., and C.W. performed experiments, developed methods, analyzed results, helped to write the manuscript, and provided intellectual input. K.G., M.H., and J.-F.P. performed experiments and provided intellectual input. B.N. performed experiments. A.B., Y.F., L.L., and F.P. performed the surgeries and provided intellectual input. I.L. provided equipment for experiments and intellectual input. C.A. produced pathology reports and provided intellectual input. A.L., L.B., and C.W. performed experiments, developed methods, analyzed results, helped to write the manuscript, and provided intellectual input. K.G., M.H., and J.-F.P. performed experiments and provided intellectual input. B.N. performed experiments. A.B., Y.F., L.L., and F.P. performed the surgeries and provided intellectual input. I.L. conceived the project, analyzed data, secured funding, and wrote the manuscript. All authors contributed to the manuscript and approved it for submission.

ACKNOWLEDGMENTS

This work was supported by funding to E.A.W. from the Canadian Institutes of Health Research. The acquisition of a GC–MS was supported by a John R. Evans Leaders equipment and infrastructure grant (#386822) from the Canada Foundation for Innovation (CFI) awarded to E.A.W. L.F.P. received scholarships from the Fonds de soutien à la recherche Joseph-Demers de la Faculté de médecine — Université Laval, the Fondation du CHU de Québec — Université Laval, the Centre de recherche sur le cancer de l’Université Laval and the CIHR. K.G. was supported by a CIHR doctoral scholarship and a Fonds de Recherche du Québec — Santé doctoral scholarship. A.L. received scholarships from the Fondation du CHU de Québec — Université Laval, the Fonds de recherche et d’enseignement de la Faculté de médecine — Université Laval and the Citoyenne du monde scholarship from Université Laval. E.A.W. holds a Tier 2 Canada Research Chair from CIHR on targeting metabolic vulnerabilities in hormonal-dependent cancers. I.L. is a Junior 1 Scholar from the Fonds de Recherche du Cancer.
CONFLICT OF INTEREST

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

APPENDIX A. SUPPLEMENTARY DATA

Supplementary data to this article can be found online at https://doi.org/10.1016/j.molmet.2022.101516.

REFERENCES

[1] Costello, L.C., Franklin, R.B., Jan 2017. Decreased zinc in the development and progression of malignancy: an important common relationship and potential for prevention and treatment of carcinomas. Expert Opinion on Therapeutic Targets 21(1):51–66. https://doi.org/10.1080/14728222.2017.1265506.

[2] Cutruzzola, F., Giardina, G., Marani, M., Macone, A., Paiardini, A., Rinaldo, S., et al., 2017. Glucose metabolism in the progression of prostate cancer. Frontiers in Physiology 8:97. https://doi.org/10.3389/fphys.2017.00097.

[3] Costello, L.C., Franklin, R.B., Feng, P., Jun 2005. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion 5(3):143–153. https://doi.org/10.1016/j.mito.2005.02.001.

[4] Massie, C.E., Mills, I.G., Lynch, A.G., Feb 2017. The importance of DNA methylation in prostate cancer development. The Journal of Steroid Biochemistry and Molecular Biology 166:1–15. https://doi.org/10.1016/j.jsbmb.2016.04.009.

[5] Owen, D.H., Katz, D.F., Jul-Aug 2005. A review of the physical and chemical properties of human semen and the formulation of a semen simulant. Journal of Andrology 26(4):459–469. https://doi.org/10.2164/jandrol.04104.

[6] Beigi Harchegani, A., Irandoost, A., Mirnamniha, M., Rahmani, H., Shemshaki, G., Murthy, A.S.N., Malini, S.S., Apr-Jun 2021. Assessment and nuclear magnetic resonance spectroscopically determined citrate in human seminal plasma. Urology 173(2):433–438. https://doi.org/10.1016/j.urology.2019.05.020.

[7] Chen, J., Guccini, I., Di Miti, D., Brina, D., Revandiukar, A., Sarti, M., et al., Jan 15 2018. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics. https://doi.org/10.1038/s41588-017-0020-3.

[8] Twum-Ampofo, J., Fu, D.X., Passaniti, A., Hussain, A., Siddiqui, M.M., Feb 22 2016. Metabolic targets for potential prostate cancer therapeutics. Current Urology 173(2):433–438. https://doi.org/10.1016/j.urology.2019.05.020.

[9] Costello, L.C., Franklin, R.B., Dec 01 2016. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Archives of Biochemistry and Biophysics 611:100–112. https://doi.org/10.1016/j.abb.2016.04.014.

[10] Costello, L.C., Franklin, R.B., 2006. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Molecular Cancer 5:17. https://doi.org/10.1186/1476-4598-5-17.

[11] Wu, X., Daniels, G., Lee, P., Monaco, M.E., 2014. Lipid metabolism in prostate cancer. American Journal of Clinical and Experimental Urology 2(2):111–120 [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/25374912.

[12] Beigi Harchegani, A., Irandoost, A., Mirnamniha, M., Rahmani, H., Shemshaki, G., Murthy, A.S.N., Malini, S.S., Apr-Jun 2021. Assessment and nuclear magnetic resonance spectroscopically determined citrate in human seminal plasma. Urology 173(2):433–438. https://doi.org/10.1016/j.urology.2019.05.020.

[13] Chen, J., Guccini, I., Di Miti, D., Brina, D., Revandiukar, A., Sarti, M., et al., Jan 15 2018. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics. https://doi.org/10.1038/s41588-017-0020-3.

[14] Chen, J., Guccini, I., Di Miti, D., Brina, D., Revandiukar, A., Sarti, M., et al., Jan 15 2018. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics. https://doi.org/10.1038/s41588-017-0020-3.

[15] Chen, J., Guccini, I., Di Miti, D., Brina, D., Revandiukar, A., Sarti, M., et al., Jan 15 2018. Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nature Genetics. https://doi.org/10.1038/s41588-017-0020-3.
[28] Giovacchini, G., Giovannini, E., Leoncini, R., Riondato, M., Giarniello, A., Sep 2017. PET and PET/CT with radiolabeled choline in prostate cancer: a critical reappraisal of 20 years of clinical studies. European Journal of Nuclear Medicine and Molecular Imaging 44(10):1751–1776. https://doi.org/10.1007/s00259-017-3700-x.

[29] Beauregard, J.M., Blouin, A.C., Fradet, V., Caron, A., Fradet, Y., Lemay, C., et al., Mar 03 2015. FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy. Cancer Imaging 15:2. https://doi.org/10.1038/cin.2015.17.

[30] Harkonen, P., Oct 1981. Androgenic control of glycolysis, the pentose cycle and pyruvate dehydrogenase in the rat ventral prostate. Journal of Steroid Biochemistry 14(10):1075–1084 [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/7300327.

[31] Liu, Y., Franklin, R.B., Costello, L.C., Jan 01 1997. Prolactin and testosterone regulation of mitochondrial zinc in prostate epithelial cells. The Prostate 30(1):26–32 [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/9018332.

[32] Costello, L.C., Liu, Y., Franklin, R.B., Jul 1995. Testosterone stimulates the biosynthesis of m-acatase and citrate oxidation in prostate epithelial cells. Molecular and Cellular Endocrinology 112(1):45–51. https://doi.org/10.1016/0303-7207(95)03582-r.

[33] Costello, L.C., Franklin, R.B., 1989. Prostate epithelial cells utilize glucose and aspartate as the carbon sources for net citrate production. The Prostate 15(4):335–342 [Online]. Available: https://www.ncbi.nlm.nih.gov/pubmed/2594584.

[34] Lacouture, A., Jobin, C., Weidmann, C., Berthiaume, L., Bastien, D., Lavenderie, I., et al., 2021. A FACs-free puriﬁcation method to study estrogen signaling, organoid formation, and metabolic reprogramming in mammmary epithelial cells. Frontiers in Endocrinology 12(67246).

[35] Fiehn, O., 2016. Metabolomics by gas chromatography–mass spectrometry: combined targeted and untargeted profiling. Current Protocols in Molecular Biology 114(1), 2021/06/17/15:38:26 [Online]. Available: https://onlinelibrary.wiley.com/doi/10.1002/0471142727.mib3004s114.

[36] Patel, D.P., Krausz, K.W., Xie, C., Beyoglu, D., Gonzalez, F.J., Idle, J.R., 2017. Metabolic proﬁling by gas chromatography–mass spectrometry of energy metabolism in high-fat diet-fed obese mice. PLoS One 12(5):e0177953, 2021/06/17/15:40:49 [Online]. Available: https://dx.plos.org/10.1371/journal.pone.0177953.

[37] Deblais, G., Smith, H.W., Tam, I.S., Gravel, S.P., Caron, M., Savage, P., et al., Jul 12 2016. ERRalpha mediates metabolic adaptations driving lapatinib resistance in breast cancer. Nature Communications 7:12156. https://doi.org/10.1038/ncomms12156.

[38] McGuirk, S., Gravel, S.P., Deblais, G., Papadopoli, D.J., Faubert, B., Wegner, A., et al., Dec 05 2013. PGC-1 alpha supports glutamine metabolism in breast cancer. Cancer & Metabolism 1(1):22.https://doi.org/10.1186/2049-3002-1-22.

[39] McCray, T., Pacheco, J.V., Loitz, C.C., Garcia, J., Baumann, B., Schlicht, M.J., et al., Jun 22 2021. Vitamin D sufﬁciency enhances differentiation of patient-derived prostate epithelial organoids. iScience 24(1):101974. https://doi.org/10.1016/j.isci.2020.101974.

[40] Richards, Z., McCray, T., Marsili, J., Zenner, M.L., Manlucu, J.T., Garcia, J., et al., Feb 22 2019. Prostate stroma increases the viability and maintains the branching phenotype of human prostate organoids. iScience 12:304–317. https://doi.org/10.1016/j.isci.2019.01.028.

[41] Drost, J., Karthaus, W.R., Gao, D., Driehuis, E., Sawyer, C.L., Chen, Y., et al., Feb 2016. Organoid culture systems for prostate epithelial and cancer tissue. Nature Protocols 11(2):347–358. https://doi.org/10.1038/nprot.2016.006.

[42] Karthaus, W.R., laquinta, P.J., Drost, J., Gracanin, A., van Boxtel, R., Wongvipat, J., et al., Sep 25 2014. Identification of multipotent luminal progenitor cells in human prostate organoid cultures. Cell 159(1):163–175. https://doi.org/10.1016/j.cell.2014.08.017.